23andMe, Genentech ask Avastin users to spit for science

08/8/2013 | Forbes

23andMe and Roche's Genentech unit are collaborating on an effort to identify genetic mutations that determine how patients respond to the cancer drug Avastin. The InVite Study asks patients who have taken Avastin for certain types of cancer to submit a saliva sample and possibly a blood sample, and answer questions in an online survey about their cancer and experience with Avastin. The study is part of a larger trend to involve patients and integrate technology in medicine, health care communications expert John Nosta writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA